Patient recruitment update: Enrollment ongoing for #CHANCE phase 2 to define futility criteria for #livertransplant in severe acute-on-chronic liver failure #ACLF. Of 56 patients recruited from 14 hospitals across Europe, Latin America, and North America, 32 have been transplanted and 24 are on waiting list. Learn more about CHANCE phase 2 at https://lnkd.in/dBWsh_NH The CHANCE study is sponsored by the European Foundation for the Study of Chronic Liver Failure (EF CLIF), and counts with the support of ESOT - European Society for Organ Transplantation and the International Liver Transplantation Society
European Foundation for the Study of Chronic Liver Failure (EF CLIF)’s Post
More Relevant Posts
-
ILTS would like to welcome you to the first-ever Special Latin American Liver Transplant Session held at #ILTS2024! Learning Objectives: -To discuss the current reality, overview and challenges of #LiverTransplantation in #LatinAmerica. -To learn about the differences in indications, prioritization and #MELD exceptions throughout Latin American countries. -To evaluate the regional efforts to maximize deceased donor and living donor liver transplantation. -To compare transplant registries and financial coverage for liver transplantation in different countries. More information https://loom.ly/UNrqxwY
-
-
Calcineurin inhibitors promote chronic alloimmunity via propagation of central memory T cell subsets DOI: 10.1016/j.ajt.2024.11.020 AJT November 22, 2024 CNIs have been the standard of care in kidney, heart, lung, and liver transplantation for the past 4 decades, but new evidence suggests that although CNIs are effective at attenuating acute alloimmune responses, they may in fact be implicated in the pathogenesis of chronic alloimmunity—a scourge that continues to affect SOT recipients
-
-
Asset assessment for in licensing and out licensing, R&D, US FDA IND Regulatory Submission for BTD/ODD/AA, Global/local Clinical Studies, Board of Directors, International Speaker, CDP, M&A, Hiring, CME advice, Editor.
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial https://lnkd.in/grxPqa_5
-
“Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients” The transplant group from Rotterdam analyzed the risk factors for Hepatic Artery Thrombosis after liver transplant and the protective role of antiplatelet prophylaxis. Read more here: https://lnkd.in/dcYHp2ec #liver #transplant #thrombosis #riskfactors #antiplatelet #prophylaxis Jeroen de Jonge Wojciech Polak Robert Porte Sarwa Darwish Mourad ESOT - European Society for Organ Transplantation
-
-
From the #StemCellEvidence Alert: Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial by Russo et al. https://lnkd.in/e-AuSAnh
-
-
Critical review (DOI: 10.1016/j.hbpd.2024.01.003) suggests liver transplantation could serve as an alternative treatment for certain patients with peri-hilar cholangiocarcinoma, offering potentially better long-term survival compared to chemotherapy. Eligibility for liver resection or transplantation requires careful patient selection and should be performed at specialized centers, emphasizing a multidisciplinary approach to treatment. #LiverCancer #Transplantation #SurgicalOncology #PatientCare #ClinicalPractice
-
-
Professor of Clinical Surgery and Medical Director, Intestinal Rehabilitation and Transplant Center, University of Illinois at Chicago; Director, Gastroenterology at Elevance Health
See the newest issue of Gastroenterology Clinics of North America: the first of a two part series from the world's experts on intestinal transplantation. Look for a future issue next year on living donor transplantation.
-
🔔Have you seen this week's #TTSPulse, which includes a special Society of Pediatric Liver Transplantation theme?! Hear from SPLIT leadership about the organization's mission and future goals, as well as advances in pediatric liver transplantation. Read here 👉 https://lnkd.in/g4jd6bGU
-
-
According to the latest results presented at #ESMOGI24, liver transplantation alongside chemotherapy shows remarkable results in a highly selected patient population with unresectable colorectal liver metastases. The TRANSMET trial reveals that this approach could quadruple the 5-year overall survival rate compared to chemotherapy alone. Read the #ESMODailyReporter to learn more about these findings in #ColorectalCancer. 👇 https://ow.ly/kt4M50SqOtY
-
-
Cohosts Roslyn Mannon, MD and Josh Levitsky, MD are joined by Mackenzie Morris, MD to discuss the key articles of the July issue of the American Journal of Transplantation. https://lnkd.in/dcafHRRs [03:33] Biliary complications after adult-to-adult living-donor liver transplantation: An international multicenter study of 3633 cases https://lnkd.in/dczyw9Zi [13:07] The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation https://lnkd.in/dMM6gsfF [24:30] Should advanced perfusion be the standard of care for donation after circulatory death liver transplant? https://lnkd.in/dG4_N2G2 [32:20] Immunosuppression Withdrawal in Living-donor Renal Transplant Recipients Following Induction with Anti-thymocyte Globulin and Rituximab: Results of a Prospective Clinical Trial https://lnkd.in/dnyQTAT2 [40:30] Spatial multiomics of arterial regions from cardiac allograft vasculopathy rejected grafts reveal novel insights into the pathogenesis of chronic antibody-mediated rejection https://lnkd.in/dgVKdDrV
-
